These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33810903)

  • 1. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season.
    Pelton SI; Divino V; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G; Postma MJ
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
    McGovern I; Chastek B; Bancroft T; Webb N; Imran M; Pelton SI; Haag MDM
    Int J Infect Dis; 2024 Sep; 146():107160. PubMed ID: 38969330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
    Levin MJ; Divino V; Shah D; DeKoven M; Mould-Quevedo J; Pelton SI; Postma MJ
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes.
    McConeghy KW; Davidson HE; Canaday DH; Han L; Saade E; Mor V; Gravenstein S
    Clin Infect Dis; 2021 Dec; 73(11):e4237-e4243. PubMed ID: 32882710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019-2020 US Influenza Season.
    Imran M; Mills CW; McDermott KW; Dean A; Bogdanov A; McGovern I; Haag MDM
    Open Forum Infect Dis; 2024 Aug; 11(8):ofae459. PubMed ID: 39170829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R; Gibbons I; Moss J; Mealing S; Largeron N; Carroll S; Alvarez FP
    J Med Econ; 2021; 24(1):1261-1271. PubMed ID: 34726129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated health and economic impact of using high-dose influenza vaccine on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia.
    Raina MacIntyre C; Kevin Yin J; Felter C; Menzies RI; Thommes E; Largeron N; Moa AM; Trent M; Costantino V; Choi S; Alvarez FP
    Vaccine X; 2023 Dec; 15():100365. PubMed ID: 37609557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Lopez-Gonzalez L; Dean A; Bonafede M; Haag MDM
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13288. PubMed ID: 38644564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons.
    Lapi F; Domnich A; Marconi E; Rossi A; Cricelli C
    Expert Rev Vaccines; 2022 Nov; 21(11):1647-1653. PubMed ID: 35984048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
    Coleman BL; Sanderson R; Haag MDM; McGovern I
    Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
    Pott H; Andrew MK; Shaffelburg Z; Nichols MK; Ye L; ElSherif M; Hatchette TF; LeBlanc J; Ambrose A; Boivin G; Bowie W; Johnstone J; Katz K; Lagacé-Wiens P; Loeb M; McCarthy A; McGeer A; Poirier A; Powis J; Richardson D; Semret M; Smith S; Smyth D; Stiver G; Trottier S; Valiquette L; Webster D; McNeil SA; ;
    Vaccine; 2023 Oct; 41(42):6359-6365. PubMed ID: 37696717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States.
    Net P; Colrat F; Nascimento Costa M; Bianic F; Thommes E; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A56-A69. PubMed ID: 33509695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.
    Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G
    Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.
    Levin MJ; Divino V; Postma MJ; Pelton SI; Zhou Z; DeKoven M; Mould-Quevedo J
    Expert Rev Vaccines; 2024; 23(1):124-136. PubMed ID: 38073493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.